Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma (RAINBOW)

13 juli 2026 uppdaterad av: Gao-Jun Teng, Zhejiang Cancer Hospital

Transcatheter Arterial Chemoembolization in Combination With Tislelizumab Plus Lenvatinib Versus Systemic Cisplatin Plus Gemcitabine in Combination With Tislelizumab for Unresectable Intrahepatic Cholangiocarcinoma: A Phase III, Multicenter, Randomized Controlled Trial

This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and cisplatin (GEMCIS) in combination with tislelizumab as first-line treatment for patients with unresectable intrahepatic cholangiocarcinoma.

Approximately 140 eligible patients with histologically confirmed unresectable intrahepatic cholangiocarcinoma without extrahepatic metastasis will be enrolled and randomized in a 1:1 ratio to receive either TACE plus tislelizumab and lenvatinib or GEMCIS plus tislelizumab. In the TACE-based treatment arm, hepatic arterial infusion chemotherapy with gemcitabine and cisplatin may be administered during or after TACE at the investigator's discretion according to the protocol.

The primary endpoint is overall survival. Secondary endpoints include progression-free survival, time to progression, objective response rate, disease control rate, safety, and quality of life.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

140

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • Guangdong
      • Guangzhou, Guangdong, Kina, 510060
      • Guangzhou, Guangdong, Kina, 510317
        • Guangdong Second People's Hospital
        • Kontakt:
      • Guangzhou, Guangdong, Kina, 510168
        • Jinshazhou Hospital of Guangzhou University of Chinese Medicine
        • Kontakt:
      • Guangzhou, Guangdong, Kina, 511400
        • The Affiliated Panyu Central Hospital of Guangzhou Medical University
        • Kontakt:
      • Guangzhou, Guangdong, Kina, 524003
        • The Second Affiliated Hospital of Guangdong Medical University
        • Kontakt:
      • Jiangmen, Guangdong, Kina, 529030
        • Jiangmen Central Hospital
        • Kontakt:
          • Yuchuang Liang
          • Telefonnummer: +86 13322888181
          • E-post: jmlyc@21cn.com
    • Hubei
      • Wuhan, Hubei, Kina, 430022
        • Wuhan Union Hospital of China
        • Kontakt:
    • Hunan
      • Changsha, Hunan, Kina, 410013
        • The Third XIANGYA Hospital of Central South University
        • Kontakt:
      • Changsha, Hunan, Kina, 410011
        • The Second Xiangya Hospital of Central South University
        • Kontakt:
    • Jiangxi
      • Ganzhou, Jiangxi, Kina, 341000
        • Ganzhou Hospital-Nanfang Hospital, Southern Medical University
        • Kontakt:
      • Nanchang, Jiangxi, Kina, 330209
        • The First Affiliated Hospital of Nanchang University
        • Kontakt:
    • Shandong
      • Qingdao, Shandong, Kina, 266000
        • The Affiliated Hospital of Qingdao University
        • Kontakt:
    • Sichuan
      • Chengdu, Sichuan, Kina, 610041
        • West China School of Medicine/West China Hospital, Sichuan University (WCSM/WCH, SCU)
        • Kontakt:
    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310022
        • Zhejiang Cancer Hospital
        • Kontakt:
        • Kontakt:
        • Underutredare:
          • Jiaping Zheng
      • Jinhua, Zhejiang, Kina, 321000
        • Jinhua Municipal Central Hospital
        • Kontakt:
      • Lishui, Zhejiang, Kina, 323020
      • Ningbo, Zhejiang, Kina, 315010
        • Ningbo No.2 Hospital
        • Kontakt:
      • Ningbo, Zhejiang, Kina, 315048
        • Ningbo Medical Center Lihuili Hospital
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  1. Age ≥18 years.
  2. Histologically confirmed intrahepatic cholangiocarcinoma that is unresectable or recurrent after curative treatment, without extrahepatic metastasis.
  3. No prior systemic therapy or transarterial interventional therapy for intrahepatic cholangiocarcinoma.
  4. At least one measurable intrahepatic lesion according to RECIST v1.1.
  5. ECOG performance status of 0 or 1.
  6. Child-Pugh class A liver function.
  7. Life expectancy ≥3 months.
  8. Adequate hematologic, hepatic, renal, and thyroid function within 14 days before study start, defined as:

    • Absolute neutrophil count ≥1.5 × 10⁹/L;
    • Platelet count ≥75 × 10⁹/L;
    • Hemoglobin ≥90 g/L;
    • Serum albumin ≥30 g/L;
    • Total bilirubin ≤1.5 × upper limit of normal;
    • AST and ALT <1.5 × upper limit of normal, and ALP <4 × upper limit of normal;
    • TSH <1 × upper limit of normal, with T3 and T4 within the normal range;
    • Serum creatinine <1.5 × upper limit of normal and creatinine clearance ≥60 mL/min.

Exclusion Criteria:

  1. Diffuse infiltrative liver lesions.
  2. Contraindications to TACE.
  3. Allergy to intravenous contrast agent.
  4. pregnant or breastfeeding women, or participants planning pregnancy within 2 years / unwilling to use effective contraception.
  5. Patients with HIV or syphilis infection.
  6. Patients with concurrent malignancies or other malignancies within 5 years before enrollment.
  7. History of allogeneic organ transplantation.
  8. Severe dysfunction of the heart, kidney, or other organs.
  9. Severe clinically active infection > grade 2 according to NCI-CTC v5.0.
  10. Psychiatric illness that may affect the informed consent process; Inability to take oral medications; Participation in another drug clinical trial within 12 months before enrollment.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: TACE Plus Tislelizumab and Lenvatinib
Participants will receive tislelizumab 200 mg intravenously every 3 weeks and oral lenvatinib once daily at a starting dose of 12 mg for body weight ≥60 kg or 8 mg for body weight <60 kg. TACE will be performed after initiation of lenvatinib and may be repeated based on radiologic response, residual viable tumor, liver function, and investigator assessment. Both conventional TACE (cTACE) and drug-eluting beads TACE are allowed, and hepatic artery infusion chemotherapy may be added at investigator's discretion. Treatment will continue until clinical progression, radiologic progressive disease according to RECIST v1.1, completion of 2 years of immunotherapy, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria.
Tislelizumab 200 mg intravenously on Day 1 of each 21-day cycle, followed by maintenance tislelizumab every 3 weeks.
Oral lenvatinib once daily, 12 mg for participants with body weight ≥60 kg or 8 mg for participants with body weight <60 kg, with dose modification according to toxicity.
Conventional TACE or drug-eluting bead TACE are allowed. TACE may be repeated based on imaging assessment every 6 weeks ±7 days and investigator judgment.
Optional hepatic arterial infusion chemotherapy with gemcitabine and cisplatin may be administered during or after TACE at the investigator's discretion according to protocol-defined dose ranges.
Aktiv komparator: Gemcitabine-Cisplatin Plus Tislelizumab
Participants will receive cisplatin 25 mg/m² on Day 1 and Day 8, gemcitabine 1000 mg/m² on Days 1 and 8, and tislelizumab 200 mg on Day 1 of each 3-week cycle for up to 8 cycles. After completion of gemcitabine-cisplatin treatment, participants will continue tislelizumab 200 mg intravenously every 3 weeks. Treatment will continue until clinical progression, radiologic progressive disease according to RECIST v1.1, completion of 2 years of immunotherapy, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria.
Tislelizumab 200 mg intravenously on Day 1 of each 21-day cycle, followed by maintenance tislelizumab every 3 weeks.
Gemcitabine 1000 mg/m² intravenously on Days 1 and 8 of each 21-day cycle, up to 8 cycles.
Cisplatin 25 mg/m² intravenously on Day 1 and Day 8 of each 21-day cycle, up to 8 cycles.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Overall Survival
Tidsram: From randomization to death from any cause, assessed up to approximately 48 months
Overall survival is defined as the time from enrollment/randomization to death from any cause. Participants who withdraw are lost to follow-up or remain alive at the end of the study will be censored at the date they were last known to be alive.
From randomization to death from any cause, assessed up to approximately 48 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Progression-Free Survival
Tidsram: From randomization to disease progression or death, assessed up to approximately 48 months
Defined as the time from randomization to disease progression or death from any cause. Participants without progression or death will be censored at the last date known to be progression-free.
From randomization to disease progression or death, assessed up to approximately 48 months
Time to Progression
Tidsram: From randomization to disease progression, assessed up to approximately 48 months
Defined as the time from randomization to disease progression. Participants who die without prior progression, withdraw, are lost to follow-up, or remain progression-free at study end will be censored at the last date known to be progression-free.
From randomization to disease progression, assessed up to approximately 48 months
Objective Response Rate
Tidsram: Assessed every 6 weeks ±7 days, up to approximately 48 months
Defined as the proportion of participants achieving complete response or partial response according to RECIST v1.1.
Assessed every 6 weeks ±7 days, up to approximately 48 months
Disease Control Rate
Tidsram: Assessed every 6 weeks ±7 days, up to approximately 48 months
Defined as the proportion of participants achieving complete response, partial response, or stable disease according to RECIST v1.1.
Assessed every 6 weeks ±7 days, up to approximately 48 months
Incidence of Grade ≥3 Adverse Events
Tidsram: From first dose of study treatment through 28 days after the last dose of study treatment
Defined as the occurrence of grade 3 or higher hematologic or non-hematologic toxicities, graded according to CTCAE v5.0.
From first dose of study treatment through 28 days after the last dose of study treatment
Quality of Life Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Tidsram: Baseline and during treatment/follow-up, assessed up to approximately 48 months
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 is a 30-item questionnaire used to assess health-related quality of life in patients with cancer. Scores are linearly transformed to a 0 to 100 scale. For the global health status/quality-of-life scale and functional scales, higher scores indicate better health-related quality of life or functioning. For symptom scales and single symptom items, higher scores indicate a higher symptom burden or worse symptoms.
Baseline and during treatment/follow-up, assessed up to approximately 48 months
Quality of Life Assessed by the EuroQol Five-Dimension (EQ-5D)
Tidsram: Baseline and during treatment/follow-up, assessed up to approximately 48 months
The EuroQol Five-Dimension Three-Level Questionnaire is a standardized instrument for measuring health-related quality of life. The descriptive system includes five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored from 1 to 3, where 1 indicates no problems, 2 indicates some or moderate problems, and 3 indicates extreme problems or inability to perform the activity. Higher scores in each dimension indicate more severe problems or worse health status.
Baseline and during treatment/follow-up, assessed up to approximately 48 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Gaojun Teng, MD, Zhejiang Cancer Hospital
  • Huvudutredare: Min Kuang, MD, First Affiliated Hospital, Sun Yat-Sen University
  • Huvudutredare: Jiansong Ji, MD, The Central Hospital of Lishui City

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 juli 2026

Primärt slutförande (Beräknad)

1 januari 2030

Avslutad studie (Beräknad)

1 juli 2030

Studieregistreringsdatum

Först inskickad

30 juni 2026

Först inskickad som uppfyllde QC-kriterierna

30 juni 2026

Första postat (Faktisk)

9 juli 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

14 juli 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

13 juli 2026

Senast verifierad

1 juli 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

Individual participant data will not be shared due to privacy, ethical, and regulatory considerations.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera